Self-replicating Vehicles Based on Negative Strand RNA Viruses

Overview

Journal Cancer Gene Ther

Specialties Genetics
Oncology
Pharmacology

Date 2022 Feb 16

PMID 35169298

Authors

Kenneth Lundstrom

Affiliations

Soon will be listed here.

Abstract

Self-replicating RNA viruses have been engineered as efficient expression vectors for vaccine development for infectious diseases and cancers. Moreover, self-replicating RNA viral vectors, particularly oncolytic viruses, have been applied for cancer therapy and immunotherapy. Among negative strand RNA viruses, measles viruses and rhabdoviruses have been frequently applied for vaccine development against viruses such as Chikungunya virus, Lassa virus, Ebola virus, influenza virus, HIV, Zika virus, and coronaviruses. Immunization of rodents and primates has elicited strong neutralizing antibody responses and provided protection against lethal challenges with pathogenic viruses. Several clinical trials have been conducted. Ervebo, a vaccine based on a vesicular stomatitis virus (VSV) vector has been approved for immunization of humans against Ebola virus. Different types of cancers such as brain, breast, cervical, lung, leukemia/lymphoma, ovarian, prostate, pancreatic, and melanoma, have been the targets for cancer vaccine development, cancer gene therapy, and cancer immunotherapy. Administration of measles virus and VSV vectors have demonstrated immune responses, tumor regression, and tumor eradication in various animal models. A limited number of clinical trials have shown well-tolerated treatment, good safety profiles, and dose-dependent activity in cancer patients.

Citing Articles

Application of Pseudoinfectious Viruses in Transient Gene Expression in Mammalian Cells: Combining Efficient Expression with Regulatory Compliance.

Zauatbayeva G, Kulatay T, Ingirbay B, Shakhmanova Z, Keyer V, Zaripov M Biomolecules. 2025; 15(2).

PMID: 40001577 PMC: 11852456. DOI: 10.3390/biom15020274.

1mΨ influences the performance of various positive-stranded RNA virus-based replicons.

Miyazato P, Noguchi T, Ogawa F, Sugimoto T, Fauzyah Y, Sasaki R Sci Rep. 2024; 14(1):17634.

PMID: 39085360 PMC: 11292005. DOI: 10.1038/s41598-024-68617-y.

Pervasive RNA folding is crucial for narnavirus genome maintenance.

Fukuda M, Cai J, Bader J, Boeke J Proc Natl Acad Sci U S A. 2023; 120(26):e2304082120.

PMID: 37339222 PMC: 10293807. DOI: 10.1073/pnas.2304082120.

Recombinant viral hemorrhagic septicemia virus with rearranged genomes as vaccine vectors to protect against lethal betanodavirus infection.

Souto S, Merour E, Le Coupanec A, Lamoureux A, Bernard J, Bremont M Front Immunol. 2023; 14:1138961.

PMID: 36999033 PMC: 10043230. DOI: 10.3389/fimmu.2023.1138961.

Viral Vectors in Gene Therapy: Where Do We Stand in 2023?.

Lundstrom K Viruses. 2023; 15(3).

PMID: 36992407 PMC: 10059137. DOI: 10.3390/v15030698.

References

Lundstrom K . Viral Vectors in Gene Therapy. Diseases. 2018; 6(2). PMC: 6023384. DOI: 10.3390/diseases6020042. View

Bloom K, van den Berg F, Arbuthnot P . Self-amplifying RNA vaccines for infectious diseases. Gene Ther. 2020; 28(3-4):117-129. PMC: 7580817. DOI: 10.1038/s41434-020-00204-y. View

Samulski R, Muzyczka N . AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu Rev Virol. 2016; 1(1):427-51. DOI: 10.1146/annurev-virology-031413-085355. View

Strauss J, Strauss E . The alphaviruses: gene expression, replication, and evolution. Microbiol Rev. 1994; 58(3):491-562. PMC: 372977. DOI: 10.1128/mr.58.3.491-562.1994. View

Frolov I, Hoffman T, Pragai B, Dryga S, Huang H, Schlesinger S . Alphavirus-based expression vectors: strategies and applications. Proc Natl Acad Sci U S A. 1996; 93(21):11371-7. PMC: 38064. DOI: 10.1073/pnas.93.21.11371. View

Liljestrom P, Garoff H . A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y). 1991; 9(12):1356-61. DOI: 10.1038/nbt1291-1356. View

Xiong C, Levis R, Shen P, Schlesinger S, Rice C, Huang H . Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science. 1989; 243(4895):1188-91. DOI: 10.1126/science.2922607. View

Davis N, Willis L, Smith J, Johnston R . In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology. 1989; 171(1):189-204. DOI: 10.1016/0042-6822(89)90526-6. View

Lundstrom K . Self-Amplifying RNA Viruses as RNA Vaccines. Int J Mol Sci. 2020; 21(14). PMC: 7404065. DOI: 10.3390/ijms21145130. View

10.

Walpita P, Flick R . Reverse genetics of negative-stranded RNA viruses: a global perspective. FEMS Microbiol Lett. 2005; 244(1):9-18. DOI: 10.1016/j.femsle.2005.01.046. View

11.

Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C . Rescue of measles viruses from cloned DNA. EMBO J. 1995; 14(23):5773-84. PMC: 394696. DOI: 10.1002/j.1460-2075.1995.tb00266.x. View

12.

Muhlebach M . Vaccine platform recombinant measles virus. Virus Genes. 2017; 53(5):733-740. PMC: 7089060. DOI: 10.1007/s11262-017-1486-3. View

13.

Schneider H, Spielhofer P, Kaelin K, Dotsch C, Radecke F, Sutter G . Rescue of measles virus using a replication-deficient vaccinia-T7 vector. J Virol Methods. 1997; 64(1):57-64. DOI: 10.1016/s0166-0934(96)02137-4. View

14.

Martin A, Staeheli P, Schneider U . RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacies of two different members of the Mononegavirales independently of the site of viral genome replication. J Virol. 2006; 80(12):5708-15. PMC: 1472609. DOI: 10.1128/JVI.02389-05. View

15.

Schnell M, Buonocore L, Kretzschmar E, Johnson E, Rose J . Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles. Proc Natl Acad Sci U S A. 1996; 93(21):11359-65. PMC: 38062. DOI: 10.1073/pnas.93.21.11359. View

16.

Tani H, Morikawa S, Matsuura Y . Development and Applications of VSV Vectors Based on Cell Tropism. Front Microbiol. 2012; 2:272. PMC: 3260743. DOI: 10.3389/fmicb.2011.00272. View

17.

Hastie E, Grdzelishvili V . Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol. 2012; 93(Pt 12):2529-2545. PMC: 4091291. DOI: 10.1099/vir.0.046672-0. View

18.

Harty R, Brown M, Hayes F, WRIGHT N, Schnell M . Vaccinia virus-free recovery of vesicular stomatitis virus. J Mol Microbiol Biotechnol. 2001; 3(4):513-7. View

19.

Ito N, Takayama-Ito M, Yamada K, Hosokawa J, Sugiyama M, Minamoto N . Improved recovery of rabies virus from cloned cDNA using a vaccinia virus-free reverse genetics system. Microbiol Immunol. 2003; 47(8):613-7. DOI: 10.1111/j.1348-0421.2003.tb03424.x. View

20.

Osakada F, Callaway E . Design and generation of recombinant rabies virus vectors. Nat Protoc. 2013; 8(8):1583-601. PMC: 4028848. DOI: 10.1038/nprot.2013.094. View